OFIX

Orthofix Medical Inc. (OFIX) Business Model Analysis (2026)

Invetso Score: 5.8/10 — Balanced · Last Updated: 2026-08-01

Overall Score

Revenue Quality

Gross margin remains strong at 69.6%, supporting a solid core product economics profile.

Revenue efficiency is still acceptable with price-to-sales at 0.50x and asset turnover at 0.95x.

Profitability

Operating performance remains weak, with EBIT margin at -4.6% and net margin at -7.4%.

Returns are still negative, including ROIC at -3.5% and ROE at -14.1%, indicating the business is not yet generating attractive shareholder returns.

Cash Generation

Operating cash flow is positive, but free cash flow remains negative at -$15.5M TTM due to elevated capex.

Free cash flow yield is still negative at -6.5%, limiting near-term cash return quality.

Balance Sheet Capital Efficiency

Liquidity remains healthy with a current ratio of 2.84x and quick ratio of 1.67x.

Leverage is manageable, with debt-to-equity at 0.55x and net debt to EBITDA at 1.22x, but interest coverage is still negative at -1.22x.

Business Model Resilience

The company still shows a mixed resilience profile: strong gross margins and liquidity offset by weak profitability and negative free cash flow.

Working capital intensity remains elevated, with a cash conversion cycle of 233.7 days and inventory days of 265.7 days.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Orthofix Medical Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →